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Penilaian Preskripsi Antimikrobial di Kalangan Doktor Panel USM: 
Pendekatan Farmakoepidemiologi 
Abstrak 
Kajian penggunaan drug adalah penting untuk menentukan tahap 
penggunaan drug dalan sesebuah negara. Penpreskripsian tidak rasional adalah satu 
fenomena global. Banyak kajian telah dilakukan untuk mendokumenkan pola 
penggunaan antibiotik dan hasilnya menunjukkan gejala preskripsi berlebihan, 
preskripsi drug. berganda, salahguna drug, penggunaan drug mahal yang tidak perlu dan 
penggunaan antibiotik berlebihan adalah masalah yang lazim berkaitan pengunaan drug 
tidak rasional di kalangan para doktor. 
Dengan mengumpulkan data dari 2,013 borang tuntutan yang dikeluarkan 
kepada pelajar Universiti Sains Malaysia, kajian ini bertujuan untuk meneliti perbezaan 
aspek berkenaan dengah penpreskripsian antibiotik kepada pelajar. Borang tuntutan 
dipilih secara tak rambang. 
Hasil kajian menunjukkan diagnosis yang sering diberi terhadap pelajar 
Universiti Sains Malaysia ialah jangkitan saluran pernafasan atas . (59.9%), 
gastroenteritis akut (5.8%) dan jangkitan saluran kencing (4.8%). Amoksisilin adalah 
antibiotik yang sering ::1:0erikan untuk jangkitan saluran penafasan atas (65.5%) dan 
jangkitan saluran kencing (52%). Bactrim® pula adalah antibiotik yang sering diberikan 
untuk gastroenteritis akut (57.2%). 48.1% keseluruhan antibiotik dipreskripsikan 
menggunakan jenama. 11.7% borang tuntutan antibiotik tidak mengikut Senarai Drug 
Perlu WHO dan 19.6% tidak mengikt:ti Garis Panduan Piawaian Rawatan Malaysia. 
Dari jumlah keseluruhan borang tuntutan, 93% tidak ditentukan dosnya, 59.8% tidak 
ditulis bentuk dos, 72.9% tidak ditulis kekerapan dos dan 77.7% tidak ditulis tempoh 
rawatan. 1.4% antibiotik didapati mempunyai masalah kontraindikasi, 0.1% masalah 
duplikasi antibiotik dan 5.6% memberikan sating tindakan drug-drug. 
Kesimpulan kajian ini menunjukkan pola penggunaan antibiotik dikalangan 
klinik panel U.S.M. mempunyai potensi masalah seperti kekurangan pemantauan, saling 
tindakan drug yang boleh membawa kesan buruk terhadap penjagaan pesakit dan 
perlunya mendokumentasikan hasil rawatan. Terdapat doktor yang tidak mengikuti 
Garis Panduan Piawaiar. Rawatan Malaysia dan Formulasi Drug. Garispanduan mestilah 
mudah diekses bagi memperbaiki aspek penggunaan drug secara rasional. Terdapat tiga 
perkara yang memerlukan tindakan lanjut untuk memperbaiki kualiti penjagaan · 
kesihatan iaitu purata jumlah drug dalam setiap borang tuntutan, peratusan borang 
tuntutan yang mengandungi antibiotik dan peratusan antibiotik yang dipreskripsikan 
dengan nama generik. 
XVI 
i 
I 
l 
ABSTRACT 
i 
Drug utilization study is important in establishing the status of drug use 
in a particular country, irrational prescribing is a global phenomenon. Many studies 
have been carried out to document antibiotic use patterns, and indicate that over 
prescribing, multiple drug prescribing, misuse of drugs, use of unnecessary expensive I 
, drugs and overuse of antibiotics are the most common problems of irrational drug use ,...., 
t 
~ ,. 
by prescribers. 
By retrospectively recording data from 2,013 claim forms issued to 
students of Universiti Sains Malaysia during the period 1997, the study sets out to 
examine different aspects of prescribing antibiotics to students. The claim forms were 
selected non-randomly from the National Poison Center. 
Results showed that the most frequent diagnosis given to USM's students 
were upper respiratory tract infection (59.9%), acute gastroenteritis (5.8%) and urinary 
tract infection (4.8%). Amoxycillin was the most common antibiotic given in cases of 
upper respiratory tract infections (65.5%) and urinary tract infections (52%), while 
Bactrim was the most common antibiotic given in cases of acute gastroenteritis (57.2%). 
The total numbers of brand name antibiotics prescribed were 48.1 %. About 11.7% of 
the claim forms did not follow the WHO Essential .Drug List and 19.6% of the antibiotic 
claim form did not follow the Malaysian Standard Treatment Guidelines. Of the total 
claim forms, 93% had unwritten dose, 59.8% had unwritten dosage form, 72.9% had 
unwritten frequency and 77.7% had unwritten duration. It was found that 1.4% of 
XVII 
antibiotics were contraindication, 0.1% of antibiotic duplicated and 5.6% having drug-
drug interactions. 
It was concluded in this study that current usage patterns of antibiotics in 
USM's panel clinic indicate some potential problems due to inadequate monitoring for 
drug interactions, a need to document outcome, some doctors not following the 
r.r'' Malaysia Standard Treatment Guideline and drug formularies. Guideline should be 
readily accessible to improve rational drug use. The average number of drugs per claim 
,.~ forms, the percentage of claim forms with antibiotics prescribed and the percentage of 
generic antibiotics prescribed, are the three areas, which need further intervention to 
-improve the quality of health care. 
XVIII 
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CHAPTER I 
INTRODUCTION 
1.1. Background 
Drugs are being constantly developed which help to improve the quality 
as well as the life span, and if they are properly taken, they can actually reduce long-
term hospitalization and other medical costs. With the advancement of medical science, 
large numbers of pharmaceutical preparations have been made available for human use. 
Drug therapy is becoming more complex. Many new prescription drugs have been 
approved every year; as a result, thousands of pages of complex drug information on 
these and other products are released every month. 
Moreover, patients today are older and sicker. They need more potent and 
sophisticated drug therapy. Administering the wrong drug, strength, or dose; confusion 
over "look-alike" and "sound-alike" drugs; incorrect routes of administration; 
miscalculations; and errors- in prescribing and transcription happen every day in every 
kind of health-care setting. The potential for adverse drug events and medication error 
is a reality, they occur in all parts of medication use system, of which prescribing and 
administration reportedly account for majority of the errors (Donald, 2000). 
Every error is potentially tragic and costly in both human and economic 
terms, for patients and professionals alike. These lead to necessitating concern about 
their judicious use. The irrational use of drugs is a global problem affecting developing 
and developed countries alike. The misuse of drugs, which is widely prevalent, warrants 
constant monitoring, especially the antibiotics. 
J.2. Brief history of antimicrobial agents 
There are many different types of antimicrobial agents available today. By 
definition this would include anything that kills microorganisms. Discussed here are 
onlY antibiotics and antifungal agents. 
Antibiotic refers to compounds isolated from one living organism that kill 
or inhibit the growth of other organisms. Antibiotics may have e.g., antibacterial, 
antifungal, antiviral, antiparasitic, or even anticancer activity. The term is loosely used 
as a synonym for more specific categories such as anticancer, antimicrobial, or 
antibacterial drug. 
Antibiotics are still highly effective treatment for infection. There is no 
need for antibiotics unless there is bacterial infection. In many cases of infections such 
as- flu, sore throat and cough, the patient recovers whether antibiotics are given or not. If 
they are used, they have little or no effect on the course of illness. Common cold and 
cough are caused by viruses and antibiotics do not fight viruses but only bacteria. 
Therefore, the doctor should only prescribe antibiotic when there is a secondary 
bacterial infection (Geoffry, 1994). 
Since their discovery in the 1930s, antibiotics have made it possible to 
cure diseases caused by bacteria such as pneumonia, tuberculosis, and meningitis thus 
saving the lives of millions of people around the world. Antibiotics must be used 
wisely, because bacteria which are living organisms, always mutate in an effort to resist 
the drugs that can kill them. When antibiotics are used incorrectly, bacteria can adapt 
"'it•· and become resistant. Antibiotics are then no longer useful in fighting them. 
Antibiotic resistance is now a major public health issue. The correct use of 
these drugs is the best way to ensure that antibiotics remain useful in treating infections 
(Jacobson et al, 1995). 
Antifungal agent IS the drug that used mainly in the treatment and 
prophylaxis of fungal infections. They include the allylamines, several polyene 
macrolide antibiotics [including amphotericin and nystatin], other antifungal antibiotics 
[e.g. griseofulvin], imidazole derivatives [such as ketoconazole], triazole derivatives 
[such as fluconazole], some fatty acids [caprylic and propionic acid and their salts], and 
8 number of other compounds among them are amorlfine, ciclopirox olamine, 
flucytosine, haloprogin, tolnaftate, and undecenoic acid and its salts. 
1.3. Description of specific antimicrobial classes 
The following discussion of antibiotics and chemotherapeutic organizes the 
antimicrobial agents based on their mode of action in bacterial cells. 
1.3.1. Agent that interfere with cell wall formation (cell wall synthesis inhibitors) 
Cell wall synthesis inhibitors generally inhibit some step in the synthesis of 
bacterial peptidoglycan. Generally they exert their selective toxicity against eubacteria 
because human cells lack cell walls. 
Beta lactam antibiotics. Chemically, these antibiotics contain. a 4-
membered beta lactam ring. They are the products of two groups of fungi, Penicillium 
and Cephalosporium molds, and are correspondingly represented by the penicillins and 
cephalosporins. 
The beta lactam antibiotics are stereochemically related to 0-alanyl-D-
alanine, which is a substrate for the last step in peptidoglycan synthesis, the final cross-
linking between peptide side chains. Penicillins bind to and inhibit the carboxypeptidase 
and transpeptidase enzymes that are required for this step in peptidoglycan biosynthesis . 
.., 
.) 
Beta Jactam antibiotics are normally bactericidal and reqmre that cells be actively 
growing in order to exert their toxicity. Different beta lactarns differ in their spectrum of 
activity and their effect on Gram-negative rods, as well as their toxicity, stability in the 
human body, rate of clearance from blood, whether they can be taken orally, ability to 
cross the blood-brain barrier, and susceptibility to bacterial beta-lactamases. 
J.J.l.l. Penieillin 
a. Natural penicillins 
Natural penicillins, such as Penicillin G or Penicillin V, are produced by 
fermentation of Penicillium chrysogenum. They are effective against streptococcus, 
gonococcus and staphylococcus, except where resistance has developed. They are 
considered narrow spectrum since they are not effective against Gram-negative rods. 
b. Semi synthetic penicillins 
Semi-synthetic penicillins first appeared in 1959. A mold produces the 
main part of the molecule (6-aminopenicillanic acid), which can be modified chemically 
by the addition of side chains. Many of these compounds have been developed to have 
' 
distinct benefits or advantages over penicillin G, such as increased spectrum of activity 
(effectiveness against Gram-negative rods), resistance to penicillinase, effectiveness 
when administered orally, etc. Amoxycillin and Ampicillin have broadened spectra 
against Gram-negatives and are effective orally; Methicillin is penicillinase-resistant. 
Although nontoxic, penicillins occasionally cause death when administered 
to persons who are allergic to them. In the U.S. there are 300 - 500 deaths annually due 
to penicillin allergy. In allergic individuals the beta lactam molecule attaches to a serum 
protein, which initiates an lgE-mediated inflan1matory response. 
4 
c. carboxypenicillins e.g. Carbenicillin & Ticarcillin 
The first agent in this group was Carbenicillin. It is no longer in wide use 
because of the relative drawbacks including high sodium load predisposing to 
congestive heart failure and renal potassium wasting and an antiplatelet effect 
stemming from physical coating of the platelets. However, there is another derivative-
Ticarcillin. It is still in use and the total dose required is lower. The major benefit to 
this group of penicillin antibiotics is the extended spectrum of activity against Gram-
negative bacteria notably pseudomonas species as well as the anaerobes. 
d. Uridopenicillins e.g. Mezlocillin, Azocillin, :Piperacillin 
The most recent development in the penicillin group is Uridopenicillins. 
These are now in common use due to their very broad spectrum. These antibiotics 
combine some of the good features of ampicillin (coverage of Enterococci and 
Hemophilus species) with the advantage of the Carboxypenicillins (good Pseudomonas 
and other Gram-negative bacterial coverage and good anaerobic coverage). However, 
resistance can be encountered due to beta-lactamases. Therefore, the Uridopenicillins 
are often combined with another agent such as an Aminoglycosides in serious infection. 
1.3.1.2. Cephalosporins 
Cephalolsporins are beta lactam antibiotics with a similar mode of action to 
penicillins that are produced by species of Cephalosporium. They have a low toxicity 
and a somewhat broader spectrum than natural penicillins. They are often used as 
penicillin substitutes, against Gram-negative bacteria, and in surgical prophylaxis. They 
are subject to degradation by some bacterial beta lactamases, but they tend to be 
resistant to beta-lactamases from S. aureus. 
5 
Table 1.1 Partial lists of cephalosporins antibiotics 
,.-First ~eneration Second generation Third generation Fourth generation 
-cefazolin -cefoxitin -moxalactam -cefepim 
-cephapirin -cefacl or( oral) -cefotaxime 
-cephalexin( oral) -cefotetan -cefoperazone 
-cefadroxil( oral) -cefuroxime -ceftriaxone 
-cefamandole -ceftazidime 
-cefonocid 
First Generation 
It is relatively broad-spectrum antibiotics. Primarily used as an effective 
antistaphylococcal agent. It covers skin flora and many Gram-negative bacteria as well. 
Seeond Generation 
Extends spectrum by including more Gram-negative bacilli. It's used· 
primarily for the coverage of specific groups of organisms, example: cefoxitin is a good 
anaerobic drug and covers some anaerobes resistant to penicillin. It is also less toxic 
than clindamycin or chloramphenicol and is used in diabetic foot ulcers and nosocomial 
aspiration pneumonia where mixed Gram-positive and anaerobic bacteria are often 
encountered. Most second-generation compounds have some activity against indole-
positive Proteus, Enterobacter , and H injluenzae. 
Third Generation 
It is a much broader Gram-negative spectrum antibiotic. It is often 
employed in cases of suspected etiology. Via chemical modification some have very 
long half-life (e.g. ceftriaxone) so the number of doses required per day is reduced. 
Fourth generation 
It is used in the treatment of complicated and uncomplicated urinary tract 
infection, skin infection caused by streptococcus pyogenes; and have activity against 
gram-negative organisms (Charles et al, 200 l ). 
6 
Disadvantages of cephalosporins (especially later generations) 
The later generations are more expensive. Less staphylococcal coverage 
,.,ith znd and 3rd generations compared to 1st generation. Penicillins and cephalosporins 
both contain a beta-lactam ring. Organisms may become resistant to them via the action 
of a beta-lactamase enzyme. 
J.J.1.3. Clavulanic acid 
Clawlanic acid Is a chemical sometimes added to a semisynthetic 
penicillin preparation. Thus, amoxycillin plus clawlanate is £1avamox or augmentin. 
The clawlanate is not an antimicrobial agent. It inhibits beta lactamase enzymes and 
has given extended life to penicillinase-sensitive beta lactams. 
1.3.1.4. Other agent that interfere with cell wall formation 
Two other classes of beta lactams are the earbapenems and 
monobactams. The latter are particularly useful for the treatment of allergic 
individuals. A person who becomes allergic to penicillin usually becomes allergic to the 
cephalosporins and the carbapenems as well. Such individuals can still be treated with 
the monobactams, which are structurally different so as not to induce allergy. 
Bacitracin is a polypeptide antibiotic produced by Bacillus species. It 
' prevents cell wall growth by inhibiting the release of the muropeptide subunits of 
peptidoglycan from the lipid carrier molecule that carries the subunit to the outside of 
the membrane. Teichoic acid synthesis, which requires the same carrier, is also 
inhibited. Bacitracin has a high toxicity, which precludes its systemic use. It is present 
in many topical antibiotic preparations, and since the gut does not absorb it, it is given 
to "sterilize" the bowel prior to surgery. 
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Cycloserine inhibits the early stages of murein synthesis where D-alanyl-
D-alanine is added to the growing peptide side chain. The antibiotic resembles D-
aJanine in spatial structure, and it competitively inhibits the racemase reaction that 
converts L-alanine to D-alanine and the synthetase reaction that joins two D-alanine 
molecules. The affinity of cycloserine for these enzymes is about a hundred times 
greater than that of D-alanine. Cycloserine enters bacterial cells by means of an active 
transport system for glycine and can reach a relatively high intracellular concentration. 
This concentrating effect, along with its high affinity for susceptible enzymes, enables 
cycloserine to function as a very effective antimicrobial agent. However, it is fairly 
toxic and has limited use as a secondary drug for tuberculosis. 
Glycopeptides, such as the antibiotic vancomycin, appear to inhibit both 
transglycosylation and transpeptidation reactions during peptidoglycan assembly. They 
bind to the muropeptide subunit as it is transferred out of the cell cytoplasm and inhibit 
subsequent polymerization reactions. Vancomycin is not effective against Gram-
negative bacteria because it cannot penetrate their outer membrane. However, it has 
become important in clinical usage for treatment of infections by strains of 
Staphylococcus aureus that are resistant to virtually all other antibiotics. 
1.3.1.5. Major limitation of beta-lactam antibiotics 
It is not toxic, but rather the fact that a significant portion of the 
population is allergic to them. Penicillin allergy should not contraindicate the 
administration of cephalosporins unless the reaction is of the immediate type 
(angioneurotic edema, or urticaria). 
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. ,. J.3.2 Protein inhibitor class of antibiotics (Protein synthesis inhibitors) 
Many therapeutically useful antibiotics owe their action to inhibition of 
some steps in the complex process of protein synthesis. Their attack is always at one of 
the events occurring on the ribosome and never at the stage of amino acid activation or 
attachment to a particular tRNA. Most have an affinity or specificity for 70S (as 
opposed to 80S) ribosomes, and they achieve their selective toxicity in this manner. The 
most important antibiotics with this mode of action are the tetracyclines, 
cbloramphenicol, the macrolides (e.g. erythromycin) and the aminoglycosides (e.g. 
streptomycin). 
1.3.2.1. Aminoglycosides 
The aminoglycosides are products oi:' Streptomyces species and are 
represented by streptomycin, kanamycin, tobramycin and gentamicin. These 
antibiotics exert their activity by binding to bacterial ribosomes and preventing the 
initiation of protein synthesis. 
Streptomycin binds to 30S subunit of the bacterial ribosome, specifically 
to the S 12 protein, which is involved in the initiation of protein synthesis. 
Experimentally, streptomycin has been shown to prevent the initiation of protein 
synthesis by blocking the binding of initiator N-formylmethionine tRNA to the 
ribosome. It also prevents the normal dissociation of ribosomes into their subunits, 
leaving them mainly in their 70S form and preventing the formation of polysomes. The 
overall effect of streptomycin seems to be one of distorting the ribosome so that it no 
longer can carry out its normal functions. This evidently accounts for its antibacterial 
activity but does not explain its bactericidal effects, which distinguishes streptomycin 
and other aminoglycosides from most other protein synthesis inhibitors. 
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Kanamycin and tobramycin have been reported to bind to the ribosomal 
30S subunit and to prevent it from joining to the 50S subunit during protein synthesis. 
They may have a bactericidal effect because this leads to cytoplasmic accumulation of 
dissociated 30S subunits, which is apparently lethal to the cells. 
Aminoglycosides have been used against a wide variety of bacterial 
infections caused by Gram-positive and Gram-negative bacteria. Streptomycin has been 
used extensively as a primary drug in the treatment of tuberculosis. Gentamicin (a 
mixture of 3 components) is active against many strains of Gram-positive and Gram-
negative bacteria, including some strains of Pseudomonas aeruginosa. Kanamycin (a 
complex of three antibiotics, A, B and C) is active at low concentrations against many 
Gram-positive bacteria, including penicillin-resistant staphylococci. Gentamicin and 
Tobramycin are mainstays for treatment of Pseudomonas infections. An unfortunate 
side effect of aminoglycosides has tended to restrict their usage: prolonged use is known 
to impair kidney function and cause damage to the auditory nerves leading to deafuess. 
1.3.2.2. Aminocyclitol 
Spectinomycin is related to aminoglycosides. It is used to treat 
penicillin-resistant Gonorrhea. 
1.3.2.3. Chloramphenicol 
" Chloramphenicol is a protein synthesis inhibitor has a broad spectrum 
of activity but it exerts a bacteriostatic effect. It is effective against intracellular 
parasites such as the rickettsiae. Unfortunately, aplastic anemia, which is dose-related, 
develops in a small proportion (1150,000) of patients. Chloramphenicol was originally 
discovered and purified from the fermentation of a Streptomyces, but currently it is 
produced entirely by chemical synthesis. Chloramphenicol inhibits the bacterial enzyme 
to 
peptidyl transferase, thereby preventing the growth of the polypeptide chain during 
.. ~protein synthesis. 
''',"} ·:· 
Chloramphenicol is entirely selective for 70S ribosomes and does not 
,~affect 80S ribosomes. Its unfortunate toxicity towards the small proportion of patients 
.:.,t><? 
;-;~~~\ 
~who receive it is in no way related to its effect on bacterial protein synthesis. However, 
~~;''since mitochondria probably originated from procaryotic cells and have 70S ribosomes, 
.,.;,;;,;r 
:· .. \;·· fl: they are subject to inhibition by some of the protein synthesis inhibitors including 
I ~· c:hloroamphenicol. This likely explains the toxicity of chloramphenicol. The eukaryotic 
cells most likely to be inhibited by chloramphenicol are those undergoing rapid 
multiplication, thereby rapidly synthesizing mitochondria. Such cells include the blood 
forming cells of the bone marrow, the inhibition of which could present as aplastic 
... 
anemia. Chloramphenicol was once a highly prescribed antibiotic and a number of 
deaths from anemia occurred before its use was curtailed~ Now it is seldom used in 
human medicine except in life-threatening situations (e.g. typhoid fever). 
1.3.2.4. Clindamycin and Lincomycin 
Lincomycin and clindamycin are a miscellaneous group of protein 
synthesis inhibitors with activity similar to the macrolides. Lincomycin has activity 
against Gram-positive bacteria and some Gram-negative bacteria (Neisseria, H 
injluenzae ). Clindamycin is a derivative of lincomycin, with the same range of 
antimicrobial activity, but it is considered more effective. It is frequently used as a 
penicillin substitute and is effective against Gram-negative anaerobes (e.g. Bacteroides). 
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JJ.2.5. Macrolide 
The macrolide family of antibiotics is characterized by structures that 
contain large lactone rings linked through glycoside bonds with amino sugars. The most 
iJDportant members of the group are erythromycin and oleandomycin. Erythromycin 
is active against most Gram-positive bacteria, Neisseria, Legionel/a and Haemophilus, 
but not against the Enterobacteriaceae. Macrolides inhibit bacterial protein synthesis by 
binding to the 50S ribosomal subunit. Binding inhibits elongation of the protein by 
peptidyl transferase or prevents translocation of the ribosome or both. Macrolides are 
bacteriostatic for most bacteria but are cidal for a few Gram-positive bacteria. 
1.3.2.6. Tetracyclines 
The tetracyclines consist of eight related antibiotics, wl-"lich are all natural 
products of Streptomyces, although some can now be produced semi-synthetically or 
synthetically. Tetracycline, chlortetracycline and doxycycline are the best known. The 
tetracyclines are broad-spectrum antibiotics with a wide range of activity against both 
Gram-positive and Gram-negative bacteria. Pseudomonas aeruginosa is less sensitive 
. but is generally susceptible to tetracycline concentrations that are obtainable in the 
bladder. The tetracyclines act by blocking the binding of aminoacyl tRNA to the A site 
on the ribosome. 
Tetracyclines inhibit protein synthesis on isolated 70S or 80S (eukaryotic) 
ribosomes, and in both cases, their effect is on the small ribosomal subunit. However, 
most bacteria possess an active transport system for tetracycline that will allow 
intracellular accumulation of the antibiotic at concentrations 50 times as great as that in 
the medium. This greatly enhances its antibacterial effectiveness and accounts for its 
specificity of action. since an etiective concentration cannot be accumulated in animal 
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cells. Thus a blood level of tetracycline, which is harmless to animal tissues, can halt 
protein synthesis in invading bacteria. 
The tetracyclines have a remarkably low toxicity and minimal side effects 
when taken by animals. The combination of their broad spectrum and low toxicity has 
red to their overuse and misuse by the medical community and the widespread 
development of resistance has reduced their effectiveness. Nonetheless, tetracyclines 
still have some important uses, such as the use of doxycycline in the treatment of Lyme 
disease. 
Some newly discovered members of the tetracycline family (e.g. 
chelocardin) have been shown to act by inserting into the bacterial membrane, not by 
inhibiting protein synthesis. 
1.3.3. Antibiotics that affect cell membranes (cell membrane inhibitors) 
These antibiotics disorganize the structure or inhibit the function of 
bacterial membranes. The integrity of the cytoplasmic and outer membranes is vital to 
bacteria, and compounds that disorganize the membranes rapidly kill the cells. 
However, due to the similarities in phospholipids in eubacterial and eukaryotic 
membranes, this action is rarely specific enough to permit these compounds to be used 
systemically. The only antibacterial antibiotic of clinical importance that acts by this 
mechanism is polymyxin, produced by Bacillus polymyxis. Polymyxin is effective 
mainly against Gram-negative bacteria and is usually limited to topical usage. 
Polymyxin binds to membrane phospholipids and thereby interferes with membrane 
function. Polymyxin is occasionally given for urinary tract infections caused by 
Pseudomonas strains that are gentamicin, carbenicillin and tobramycin resistant. The 
balance between ctTcctiveness and damage to the kidney and other organs ts 
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dangerously close, and the drug should only be given under close supervision in the 
hospital. 
:'1ft;, 1.3.4. Antibiotics affecting nucleic acids 
Some antibiotics and chemotherapeutic agents affect the synthesis of DNA 
or RNA, or can bind to DNA or RNA so that their messages cannot be read. Either case, 
of course, can block the growth of cells. The majority of these drugs are unselective, 
however, and affect animal cells and bacterial cells alike and therefore have no 
therapeutic application. Two nucleic acid synthesis inhibitors, which have selective 
· activity against procaryotes, and some medical utility are the quinolones and · 
rifamyeins. 
Nalidixic acid is a synthetic chemotherapeutic agent, which has activity 
mainly against Gram-negative bacteria. Nalidixic acid belongs to a group of compounds 
called quinolones. Nalidixic acid is a bactericidal agent that binds to the DNA gyrase 
enzyme (topoisomerase), which is essential for DNA replication and allows supercoils 
to be relaxed and reformed. Binding of the drug inhibits DNA gyrase activity. 
Some quinolones penetrate macrophages and neutrophils better than most 
antibiotics and are thus useful in treatment of infections caused by intracellular 
parasites. However, the main use of nalidixic acid is in treatment of lower urinary tract 
infections (UTI). The compound is unusual in that it is effective against several types of 
Gram-negative bacteria such as E. coli, Enterobacter aerogenes, K. pneumoniae and 
Proteus species, which are common, causes of UTI. It is not usually effective against 
Pseudomonas aeruginosa, and Gram-positive bacteria are resistant. 
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Some quinolones have a broadened spectrum against Gram-positive 
bacteria. The fluoroquinolone, Cipro. ( ciprofloxacin) was recently touted as the drug of 
choice for treatment and prophylaxis of anthrax, which is caused by a Gram-positive 
bacillus. 
The rifamycins are a comparatively new group of antibiotics, also the 
products of Streptomyces. Rifampicin is a semisynthetic derivative of rifamy£in that is 
active against Gram-positive bacteria (including Mycobacterium tuberculosis) and some 
Gram-negative bacteria. Rifampicin acts quite specifically on the bacterial RNA 
polymerase and is inactive towards DNA polymerase or RNA polymerase from animal 
cells. The antibiotic binds to the beta subunit of the polymerase and apparently blocks 
,. the entry of the first nucleotide, which is necessary to activate the polymerase, thereby 
blocking mRNA synthesis. It has been found to have greater bactericidal effect against 
M tuberculosis than other anti-tuberculosis drugs, and it has largely replaced isoniazid 
as one of the front-line drugs used to treat the disease, especially when isoniazid 
resistance is indicated. It is effective orally and penetrates the cerebrospinal fluid so it is 
useful for treatment of bacterial meningitis. 
,._ 
1.3.4. Competitive inhibitors 
Many of the synthetic chemotherapeutic agents are competitive inhibitors 
of essential metabolites or growth factors that are needed in bacterial metabolism. 
,,_ Hence, these types of antimicrobial agents are sometimes referred to as· anti-
metabolites or growth factor analogs, since they are designed to specifically inhibit an 
essential metabolic pathway in the bacterial pathogen. At a chemical level, competitive 
inhibitors are structurally similar to a bacterial growth factor or metabolite, but they do 
not fulfill their metabolic function in the cell. Some are bacteriostatic and some are 
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bactericidal. Their selective toxicity is based on the premise that the bacterial pathway 
does not occur in the host. 
Sulfonamides were introduced as chemotherapeutic agents by Domagk in 
·OIIiil,· 1935, who showed that one of these compounds (prontosil) had the effect of curing 
mice with infections caused by beta-hemolytic streptococci. Chemical modifications of 
the compound sulfanilamide gave compounds with even higher and broader 
antibacterial activity. The resulting sulfonamides have broadly similar antibacterial 
• activity, but differ widely in their pharmacological actions. Bacteria, which are almost 
always sensitive to the sulfonamides, include Streptococcus pneumoniae, beta-
hemolytic streptococci and E. coli. The sulfonamides have been extremely useful in the 
treatment of uncomplicat\;d UTI caused by E. coli, and in the treatment of 
~~ 
meningococcal meningitis (because they cross the blood-brain barrier). 
The sulfonamides (e.g. Gantrisin) and Trimethoprim are inhibitors of the 
bacterial enzymes required for the synthesis of tetrahydrofolic acid (THF), the vitamin 
form of folic acid essential for 1-carbon transfer reactions. Sulfonamides are structurally 
similar to para aminobenzoic acid (PABA), the substrate for the first enzyme in the THF 
pathway, and they competitively inhibit that step. Trimethoprim is structurally similar to 
dihydrofolate and competitively inhibits the second step in THF synthesis mediated by 
the DHF reductase. Animal cells do not synthesize their own folic acid but obtain it in a 
preformed fashion as a vitamin. Since animals do not make folic acid, they are not 
affected by these drugs, which achieve their selective toxicity for bacteria on this basis. 
Three additional synthetic chemotherapeutic agents have been used in the 
treatment of tuberculosis: (INH), paraaminosalicylic acid (PAS), and ethambutol. 
The usual strategy in the treatment of tuberculosis has been to administer a single 
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antibiotic (historically streptomycin, but now, most commonly, rifampicin is given) in 
conjunction with INH and ethambutol. Since the tubercle bacillus rapidly develops 
resistance to the antibiotic, ethambutol and INH are given to prevent outgrowth of a 
resistant strain. It must also be pointed out that the tubercle bacillus rapidly develops 
resistance to ethambutol and INH if either drug is used alone. Ethambutol inhibits 
incorporation of mycolic acids into the mycobacterial cell wall. Isoniazid has been 
reported to inhibit mycolic acid synthesis in mycobacteria and since it is an analog of 
' pyridoxine (Vitamin B6) it may inhibit pyridoxine-catalyzed reactions as well. Isoniazid 
is activated by a mycobacterial peroxidase enzyme and destroys several targets in the 
cell. PAS is an anti-folate, similar in activity to the sulfonamides. PAS was once a 
primary anti-tuberculosis drug, but now it is a secondary agent, having been largely 
replaced by ethambutol. 
1.4. Problem with antibiotic use 
The concerns regarding inappropriate antibiotic use can be divided into 
four areas: efficacy, toxicity, cost and resistance. Inappropriate use of antibiotic can be 
due to:-(a) antibiotic use where no infection is present, e.g. continuation of peri-
operative prophylaxis for more than 24 hours after a clean surgery; (b) infection which 
is not amenable to antibiotic therapy, e.g. antibiotics prescribed for viral upper 
respiratory tract infection; (c) the wrong drug for the causative organism, e.g. the use of 
broad spectrum anti-Gram negative agents for community acquired pneumonia; (d) the 
wrong dose or dura~ion of therapy. Such inappropriate use has a measurable effect on 
the therapeutic efficacy. For example, one study showed that mortality in gram-negative 
septicemia is doubled when inappropriate empiric agents were used (Kreger et al, 1980). 
Since most initial antibiotic therapy is empiric, any attempt at improving the use must 
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tackle prescribing habits, with particular emphasis on the guidelines of therapy based on 
the clinical criteria. 
Inappropriate antibiotic used exposes patients to the risk of drug toxicity, 
while giving little or no therapeutic advantage. Antibiotics are often considered 
relatively safe and yet direct or indirect side effects of their use are not infrequent and 
may be life-threatening. Allergic reactions, particularly to beta-lactam agents are well 
recognized and have been described in reaction to antibiotic residues in food (Barragry, 
1994 ). Life threatening side effects may occur from the use of antibiotics for apparently 
simple infections. It is estimated that eight people per year in UK die from side effects 
of co-trimoxazole usage in the community (Robert and Edmond, 1998). Indirect side 
effects are often overlooked, especially as they may occur sometime after the antibiotic 
has been given. These include drug interactions (such as interference of antibiotic with 
anti-coagulant therapy and erythromycin with antihistamine) (BNF, 1998), side effects 
associated with the administration of antibiotics (such as intravenous cannula infection) 
and super-infection (such as candidiasis and pseudomembranous colitis). Each of these 
may have a greater morbidity, and indeed mortality, than the initial infection for which 
., the antibiotic was prescribed (Kunin et al, 1993). 
The medical benefit of antibiotics does not come cheap. In the hospital 
setting, in United States up to fifty percent of population receives one antibiotic during 
their hospital stay, with surgical prophylaxis according for thirty percent of this. The 
financial cost of this can be considerable. The antimicrobial bill for our own institution 
is approximately IR£800,000 per annum. This represents the acquisition costs of the 
drugs and does not include indirect costs (consumables, personnel, adverse etTects etc.), 
which may far outweigh the cost of the individual drugs. Given that some 50% of 
antibiotic prescriptions may be inappropriate. it is clear that major cost savings can be 
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realized through more judicious antibiotic prescribing. Similar costs are found in 
general practice where IR£10,472,854 was spent on antimicrobials in the GMS alone in 
1993 (the last year for which statistics are available) (Robert and Edmond, 1998). 
The first penicillin resistant isolate of staphylococcus aureus was described 
only two years after the introduction of penicillin. Within a decade, 90% of isolates 
were penicillin resistant. This pattern of antibiotic discovery and introduction, followed 
by exuberant use and rapid emergence of resistance has subsequently been repeated 
with each new class of antibiotics introduced. Bacteria can so rapidly develop resistance 
due to two major evolutionary advantages. Firstly, bacteria have been in existence for 
some 3.8 billion years and resistance mechanisms have evolved over this time as a 
protective mechanism against naturally occurring compounds produced by other 
microorganisms. In addition, they have an extremely rapid generation time and can 
freely exchange genetic material encoding resistance, not only between other species 
but also between genera. The vast quantities of antibiotics used in both human and 
veterinary medicine, has lead to emergence of infection due to virtually untreatable 
bacteria. Multiple drug resistant tuberculosis is already widespread in parts of Southern 
Europe and has recently caused outbreaks in two hospitals in London (Hirarnatsu et al, 
1997). 
Anti-infectives are vital drugs, but they are over-prescribed and over-used 
in the treatment of minor disorder such as simple diarrhea, cough and colds. When 
antibiotics are used too often in sub-optimal dosages, bacteria become resistant to them. 
The result is treatment failure where patient continue to sufter from serious intections 
despite taking the medication (Mohamed I, 1999). 
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Drugs prescribed are in no way beneficial to the patient's management if 
there are some negative interactions among the various agent prescribed, over 
prescribed, under prescribed or prescribed in the wrong dosage schedule. 
How does one ensure that good drugs are not badly used, misused or even 
abused? How can drugs be used rationally as intended? What is rational use of drugs? 
What does rational mean? 
1.5. Rational use of drug 
"Rational use of drugs requires that patients receive 
medications appropriate to their clinical needs, in doses 
that meet their own individual requirements for an 
adequate period of time, and the lowest cost to them and 
their community (WHO, 1985). 
These requirements will be fulfilled if the process of prescribing is 
appropriately followed. This will include steps in defining patient's problems (or 
diagnosis); in defining effective and safe treatments (drugs and non-drugs); in selecting 
appropriate drugs, dosage and duration;- in writing a prescription; in giving patients 
adequate information; and in planning to evaluate treatment responses. The definition 
implies that rational use of drugs; especially rational prescribing should meet certain 
criteria as follows (Ross et al, 1992): 
Appropriate indication. The decision to prescribe drug(s) is entirely based on medical 
rationale and that drug therapy is an effective and safe treatment. 
Appropriate drug. The selection of drugs is based on efficacy, safety, suitability and 
cost considerations. 
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Appropriate patient. No contraindications exist and the likelihood of adverse reactions 
is minimal, and the drug is acceptable to the patient. 
Appropriate information. Patients should be provided with relevant, accurate, important 
and clear information regarding his or her condition and the medication(s) that are 
prescribed. 
Appropriate monitoring. The anticipated and unexpected effects of medications should 
be appropriately monitored (Vance, 1986). 
Unfortunately, in the real world, prescribing patterns do not always 
conform to these criteria and can be classified as inappropriate or irrational prescribing. 
Irrational prescribing may be regarded as "pathological" prescribing, where the above-
mentioned criteria are nut fulfilled. Common patterns of irrational prescribing, may 
therefore be manifested in the following forms: 
1. The use of drugs when no drug therapy is indicated, e.g., antibiotics for viral 
upper respiratory infections, 
2. The use of the wrong drug for a specific condition requiring drug therapy, e.g., 
tetracycline in childhood diarrhea requiring oral rehydration salt (ORS), 
3. The use of drugs with doubtful/unproven efficacy~ e.g., the use of 
antimotility agents in acute diarrhea, 
4. The use of drugs of uncertain safety status, e.g., use of dipyrone, 
5. Failure to provide available, safe, and effective drugs, e.g., failure to vaccinate 
against measles or tetanus, failure to prescribe ORS for acute diarrhea, 
6. The use of correct drugs with incorrect administration, dosage-s, and duration, 
e.g., the use of IV metronidazole when suppositories or oral formulations would 
be appropriate. 
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7. The use of unnecessarily expensive drugs, e.g., the use of a third 
generation, broad spectrum antimicrobial when a first-line, narrow 
spectrum, agent is indicated. 
Some examples of commonly encountered inappropriate prescribing 
. practices in many health care settings include (Avom and Harvey, 1987): 
1. Overuse of antibiotics and antidiarrheals for non-specific childhood diarrhea, 
2. Multiple drug prescriptions, prescribe unnecessary drugs to counteract or 
augment drugs already prescribed, and 
3. Excessive use of antibiotics in treating minor respiratory tract infection. 
The drug use system is complex and varies from country to country. 
Drugs may be imported or manufactured locally. The drugs may be used in 
hospitals or health centers, by private practitioners and often in a pharmacyor 
drug shop where OTC preparations are sold. In some countries all drugs are 
available over the counter! Another problem among the public includes a 
very wide range of people with differing knowledge, beliefs and attitudes 
about medicines. 
1.5.1. Factors underlying irrational use of drugs 
There are many different factors that affect the irrational use of drugs. In 
addition, different cultures view drugs in different ways, and this can affect the way 
drugs are used. The major forces can be categorized as those deriving from patients, 
prescribers, the workplace, the supply system including industry influences, regulation, 
drug information and misinformation, and combinations of these factors (Ross- Degnan 
et al, 1992). 
,~ Table 1.2 Factors affecting irrational use of drug 
'"f-Patients: drug misinformation Due to the misleading beliefs of patient 
and patient demands/expectations 
~-Prescribers: lack of education and Due to inappropriate role models, lack 
training of objective drug information, 
generalization of limited experience 
'~ and misleading beliefs about drugs efficacy 
~-Workplace: heavy patient load Due to pressure to prescribe, lack of 
adequate lab capacity and insufficient 
-~·"'[ 
staffing 
.\ 4-Drug Supply System: unreliable Due to drug shortages and expired 
suppliers drugs s~ied 
5-Drug Regulation: non-essential drugs Due to non-formal prescribers and lack 
available of regulation enforcement 
6-Industry: promotional activities Due to misleading claims 
~ ).5.2. Impact of inappropriate use of drugs 
The impact of this irrational use of drugs can be seen in many ways (Avom 
and Harvey, 1987): 
I. Reduction in the quality of drug therapy leading to increased morbidity and 
mortality, 
2. Waste of resources leading to reduced availability of other vital drugs and 
increased costs,· 
3. Increased risk of unwanted effects such as adverse drug reactions and the 
emergence of drug resistance, e.g., malaria or multiple drugs resistant 
tuberculosis, 
4. Psychosocial impacts, such as when patients come to believe that there is "a pill 
for every ill". This may cause an apparent increased demand for drugs. 
The government of Malaysia has adopted the primary health care approach 
as long -term strategy for providing health care to all residents of the country. Primary 
?" _ _, 
-''·· 
' ; 
health care centers provide facilities for disease prevention and treatment, promotion of 
health and rehabilitation (MOH, 1993). 
Several local regulatory bodies have been formed to ensure that drug 
availability and prescribing in the district conrorm to the highest contemporary 
standards. Antibiotic Control Committee was formed to provide guidelines to practicing 
physicians about the use and abuse of antibiotics. The Committee is responsible for 
analyzing the pattern of antibiotic prescriptions and preparing guidelines for antibiotic 
use. The Committee produced guidelines related to antibiotics that were circulated to all 
-· physicians in the district (Marr et al, 1988). 
The guidelines emphasized the following aspects: 
1. The presence of up-to-date information about all antibiotics m each 
primary health-care center and hospital. 
2. Methods and strategies for choosing appropriate antibiotics for a specific 
disease condition. 
3. The establishment of antibiotics subcommittees in each health-care 
facility for auditing antibiotics use. The information package contained 
articles about the use and abuse of antibiotics. Worldwide meetings were 
organized with the physicians of the districts to discuss the states of 
antibiotics and the details of the guidelines. 
1.6. The rationale prescription (i.e. the right to prescribe) 
The rights to prescription writing must ensure the patient's five 
rights (i) the right drug, (ii) the right dose, (iii) by the right route, (iv) to the right patient 
and (v) at the right time. Illegible handwriting and misinterpretation of prescriptions and 
medication orders are widely recognized causes of prescription error. The medicines 
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